OncLive TV

Neil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.

Joshua Bauml, MD, discusses the utility of liquid biopsy in metastatic non–small cell lung cancer.

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses daratumumab (Darzalex)-based regimens in the frontline treatment of patients with multiple myeloma.

Madhuri Vusirikala, MD, professor of internal medicine in the Division of Hematology/Oncology at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses ongoing research with blinatumomab (Blincyto) in acute lymphoblastic leukemia (ALL).

Brian Orr, MD, an assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at University of Pittsburgh Medical Center, discusses ongoing biomarker research for immunotherapy in ovarian cancer.

Jeff Yorio, MD, discusses treatment options for patients with rare mutations in metastatic lung cancer.

Kelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

Anna C. Pavlick, DO, discusses the importance of immunotherapy for patients with metastatic melanoma.

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

David F. Penson, MD, MPH, MMHC, discusses the importance of maintaining quality of life for patients treated with androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.

Eric Shinohara, MD, MSCI, discusses the future of stereotactic body radiation and surgery in prostate cancer.

Thomas G. Martin, MD, discusses the use of selinexor in patients with triple-class refractory multiple myeloma.

A. Oliver Sartor, MD, discusses research on immunotherapy, radiopharmaceuticals, and combinations in prostate cancer.

Ilaria Iacobucci, PhD, discusses integrated transcriptomic and genomic sequencing to identify prognostic constellations of driver mutations in AML and MDS.

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

David F. Penson, MD, MPH, MMHC, discusses questions regarding next-generation androgen receptor (AR) inhibitors in prostate cancer.

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

Casey M. Cosgrove, MD, discusses the approval of niraparib in advanced ovarian cancer.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).

R. Steven Paulson, MD, discusses molecular testing in oncology.

Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Jonathan E. Brammer, MD, discusses the progression of transplant in acute lymphoblastic leukemia.

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Mika Cline, MD, discusses data with PARP inhibitors in patients with BRCA1/2 mutated pancreatic cancer.